Carlan S J, O'Brien W F, O'Leary T D, Mastrogiannis D
Department of Obstetrics and Gynecology, University of South Florida College of Medicine, Tampa.
Obstet Gynecol. 1992 Feb;79(2):223-8.
This study was designed to investigate the efficacy and safety of sulindac in the treatment of preterm labor. Thirty-six women in preterm labor who had failed initial attempts at tocolysis with magnesium sulfate were randomized to receive either oral indomethacin or oral sulindac for 48 hours. The mean gestational ages at admission were 29 and 30 weeks for the sulindac and indomethacin groups, respectively. There was a significantly greater hourly fetal urine output, deepest amniotic fluid pocket, and amniotic fluid index in the sulindac group. A trend toward higher fetal ductus arteriosus flow velocities noted in the indomethacin group was not seen in the sulindac group. The drugs had similar success in delaying delivery for 48 hours or 7 days. The mean birth weights were 2000 and 2323 g for the sulindac and indomethacin groups, respectively. Sulindac appears to be as effective as indomethacin for refractory preterm labor but with fewer fetal side effects.
本研究旨在探讨舒林酸治疗早产的疗效和安全性。36例早产且硫酸镁初始宫缩抑制治疗失败的妇女被随机分为两组，分别口服吲哚美辛或舒林酸48小时。舒林酸组和吲哚美辛组入院时的平均孕周分别为29周和30周。舒林酸组每小时胎儿尿量、最大羊水深度和羊水指数显著更高。吲哚美辛组出现胎儿动脉导管血流速度升高的趋势，而舒林酸组未出现。两种药物在延迟分娩48小时或7天方面成功率相似。舒林酸组和吲哚美辛组的平均出生体重分别为2000克和2323克。对于难治性早产，舒林酸似乎与吲哚美辛同样有效，但胎儿副作用较少。
